The latest headlines across every section, pulled from official and open-access sources.
The World Health Organization (WHO) has validated Australia for eliminating trachoma as a public health problem, marking a significant milestone in the health of indigenous peoples and in global efforts to combat neglected tropical diseases (NTDs). Trachoma, the world’s leading infectious cause of blindness, no longer represents a public health problem in the country.
Hospital patients at every NHS trust across England can now check their referrals and appointments through the NHS App, making it easier for millions of people to manage their care in one place. Around two-thirds (64%) of all hospital appointments are currently visible through the app, with many patients also able to reschedule or cancel appointments – helping to cut the number of missed […]
The U.S. Food and Drug Administration today announced two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT).
On March 31, NCQA released the HEDIS® MY 2026 Volume 2: Technical Update (Technical Update), which provides comprehensive guidance for organizations reporting HEDIS. With this release, the HEDIS Volume 2: Technical Specifications are “frozen” for MY 2026. Why is the HEDIS Technical Update Important? HEDIS is a set of standardized performance measures that enable consumers, […] The post NCQA Releases HEDIS® MY 2026 Volume 2 Technical Update appeared first on NCQA .
Heart failure (HF) affects more than 64 million individuals worldwide, and 20% to 30% of patients with HF and systolic dysfunction have cardiac dyssynchrony due to conduction system disease. JAMA Review author Mihail Chelu, MD, PhD, of Baylor College of Medicine discusses cardiac resynchronization therapy with JAMA Associate Editor David Simel, MD, MHS. Related Content: Cardiac Resynchronization Therapy Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure
Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Daiichi Sankyo
The gap between rising demand for behavioral health services and the healthcare system’s ability to deliver timely, coordinated care continues to widen. Nearly 59 million U.S. adults experience mental illness each year, yet about half do not receive treatment—creating significant downstream consequences for patients, families and the broader healthcare system. As the demand for behavioral […] The post Advancing Behavioral Health Integration in Primary Care: Turning Shared Priorities Into Action appeared first on NCQA .
On April 18, President Trump issued an Executive Order directing the U.S. Department of Health and Human Services (HHS) to accelerate access to treatments for patients with serious mental illness, including devastating, complex, and treatment-resistant conditions.
Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Merck Sharp Dohme
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy.
Public health resources can help protect individuals and their families this tick season
34 people across 13 states have gotten sick with the same strain of Salmonella
This report describes contact tracing following mpox exposures during commercial air travel.
This report describes flu vaccination coverage among nursing home residents and health care providers working in nursing homes.
CMS and FDA announce the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new pathway designed to expedite access to certain FDA-designated Class II and Class III Breakthrough Devices for people with Medicare.
This week, we explore new strategies for blood-pressure control after intracerebral hemorrhage, Covid-19 treatment in higher-risk patients, hormonal therapy for prostate cancer, and anesthesia for tracheal intubation. We review spinal epidural abscess and follow a case of progressive weakness and liver lesions. We examine advances in tRNA research, and Perspectives discuss the use AI in prescribing, pediatric drug research, the impact of pharmaceutical mergers, and the goals of care.
Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing. — SUN PHARMACEUTICAL INDUSTRIES INC · Class II · Ongoing
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality. — Xiamen Kang Zhongyuan Biotechnology Co., Ltd. · Class II · Ongoing
Chemical contamination: Presence of benzene — Owen Biosciences Inc. · Class II · Ongoing
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality. — Xiamen Kang Zhongyuan Biotechnology Co., Ltd. · Class II · Ongoing
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality. — Xiamen Kang Zhongyuan Biotechnology Co., Ltd. · Class II · Ongoing
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality. — Xiamen Kang Zhongyuan Biotechnology Co., Ltd. · Class II · Ongoing
Subpotent Drug — Island Kinetics, Inc. d.b.a. CoValence Laboratories · Class III · Ongoing